Saturday — November 14, 2015
|
Welcome! |
Ophthalmology Times welcomes ophthalmic professionals from around the world to Las Vegas. Our four-day coverage of this year’s meeting of the American Academy of Ophthalmology begins today and includes the latest research findings and clinical news of interest to readers. Enjoy the meeting! |
TOP STORIES |
The present method of lowering IOP as a means of preventing optic neuropathy is expanding beyond prostaglandin analogues and beta blockers to include novel therapeutics, such as ROCK inhibitors, the adenosine class of drugs, and nitric oxide added to prostaglandins, said John R. Samples, MD. » Read about the future of glaucoma therapy |
Glaucoma surgeons are constantly clamoring for better surgical techniques. These new procedures will have to include less follow-up, fewer complications, and be technically accessible, said Barbara Smit, MD, PhD. » Click for the answer |
When military personnel are injured in combat situations, the primary concern of saving lives supersedes saving sight, said Col. Anthony J. Johnson, MD, Fort Sam Houston, Antonio, TX. » Click to find out why |
A number of emerging infectious diseases have made recent headlines—most prominently, the Ebola virus outbreak in West Africa—prompting higher levels of vigilance, said Paul Tambyah, MD, PhD, Singapore. » Click to read how to prevent pandemics |
FROM THE SHOW FLOOR |
The approval of the Kamra corneal inlay represents a major advancement in the surgical correction of presbyopia in more than a decade, according to its manufacturer. » Click for more on the device |
Alcon Laboratories has received FDA approval for its AcrySof IQ ReSTOR +2.5 D IOL for patients undergoing cataract eye surgery who choose to address near, intermediate, and distance vision needs at the same time. » Click for more on the approval |
|
We welcome your feedback!
Please send your comments to:
Mark L. Dlugoss
Group Content Director
UBM Advanstar Eyecare Group
mdlugoss@advanstar.com |
DISCLAIMER:
This information has been independently developed and provided by the editors of Ophthalmology Times. The sponsors do not endorse and are not responsible for the accuracy of the content or for practices or standards of non-sponsor sources. These articles may discuss regimens that have not been approved by the FDA. For full prescribing information including indications, contraindications, warnings, precautions, and adverse experiences, please see the appropriate manufacturer's product circular. |
|